Prestige BioPharma Limited

₩3,880As of Sun 8 Nov 2026, 12:00 UTC
KRX:950210Healthcare
Country South Korea
PE (Fwd) •••
TSR 6Y CAGR (33.27%)
Div yield —
ROE (24.27%)
Biotechnology
Beta (5Y) 0.53
PE TTM —
TSR TTM (68.89%)
Mkt cap ₩46.63B
ROIC (16.64%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
₩4,741
22.18%
(67.65%)
Hold 12|7|6|12|6
2Q26
3Q26
4Q26
1Q27
Earnings per share₩
38.21
40.45
40.46
44.63
10.25%
9.90%
2.91%
12.67%
Revenue₩B
2.034
2.084
2.074
2.160
1.09%
(0.15%)
2.11%
4.36%
Peers (US$34.38M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
3.425
0.904
0.907
EBIT/Intx
0.963
0.739
0.540
Own earn%
(96.64)
(22.14)
(26.27)
Sh yield%
30.85
23.84
26.75
Owners
Insiders/Inst%
11.32
60.16
Short interest%
3.83
SBC / revenue%
2.52
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
15
Op margin range%
13–20
$1 testx
0.0
Incr. ROIC%
13